CA3049889A1 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Download PDFInfo
- Publication number
- CA3049889A1 CA3049889A1 CA3049889A CA3049889A CA3049889A1 CA 3049889 A1 CA3049889 A1 CA 3049889A1 CA 3049889 A CA3049889 A CA 3049889A CA 3049889 A CA3049889 A CA 3049889A CA 3049889 A1 CA3049889 A1 CA 3049889A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- phe
- pen
- lys
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447778P | 2017-01-18 | 2017-01-18 | |
| US62/447,778 | 2017-01-18 | ||
| PCT/US2018/014257 WO2018136646A1 (en) | 2017-01-18 | 2018-01-18 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3049889A1 true CA3049889A1 (en) | 2018-07-26 |
Family
ID=62908287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3049889A Pending CA3049889A1 (en) | 2017-01-18 | 2018-01-18 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200207822A1 (https=) |
| EP (1) | EP3570864B1 (https=) |
| JP (3) | JP2020505352A (https=) |
| AU (1) | AU2018210174B2 (https=) |
| CA (1) | CA3049889A1 (https=) |
| WO (1) | WO2018136646A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968443T3 (da) | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| PT3143037T (pt) | 2014-05-16 | 2021-09-24 | Protagonist Therapeutics Inc | Antagonistas peptídicos tioéter de integrina alfa4beta7 |
| US9624268B2 (en) | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| KR20170108936A (ko) | 2014-10-01 | 2017-09-27 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 신규한 α4β7 펩타이드 단량체 및 이량체 길항제 |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP4067368A1 (en) | 2016-06-01 | 2022-10-05 | Athira Pharma, Inc. | Compounds |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| CN114341161A (zh) * | 2019-07-10 | 2022-04-12 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| TW202116793A (zh) * | 2019-07-10 | 2021-05-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途 |
| HRP20250769T1 (hr) * | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti |
| AU2021209086A1 (en) * | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2023288019A2 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CA3226539A1 (en) * | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor |
| CN118354781A (zh) | 2021-12-01 | 2024-07-16 | 西兰制药公司 | 白介素-23受体的肽抑制剂 |
| CA3260606A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS |
| CN120019064A (zh) * | 2022-07-14 | 2025-05-16 | 詹森药业有限公司 | Il-23的环肽抑制剂 |
| WO2024155552A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Formulations of lipidated peptide inhibitors of interleukin-23 receptor |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| CN121909205A (zh) | 2023-09-08 | 2026-04-21 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| WO2025051920A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2026057052A1 (zh) * | 2024-09-14 | 2026-03-19 | 深圳信立泰药业股份有限公司 | 一种il-23受体抑制剂及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166138A1 (en) * | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9605027B2 (en) * | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9624268B2 (en) * | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| HK1257747A1 (zh) | 2015-07-15 | 2019-10-25 | Protagonist Therapeutics Inc. | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 |
| US20200064357A1 (en) * | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
-
2018
- 2018-01-18 WO PCT/US2018/014257 patent/WO2018136646A1/en not_active Ceased
- 2018-01-18 JP JP2019538525A patent/JP2020505352A/ja not_active Withdrawn
- 2018-01-18 US US16/478,733 patent/US20200207822A1/en not_active Abandoned
- 2018-01-18 EP EP18741939.5A patent/EP3570864B1/en active Active
- 2018-01-18 CA CA3049889A patent/CA3049889A1/en active Pending
- 2018-01-18 AU AU2018210174A patent/AU2018210174B2/en active Active
-
2022
- 2022-12-02 JP JP2022193564A patent/JP7819087B2/ja active Active
-
2023
- 2023-01-13 US US18/097,077 patent/US20240132558A1/en active Pending
-
2025
- 2025-05-28 JP JP2025088409A patent/JP2025162551A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025162551A (ja) | 2025-10-27 |
| JP2023014346A (ja) | 2023-01-26 |
| US20240132558A1 (en) | 2024-04-25 |
| WO2018136646A1 (en) | 2018-07-26 |
| EP3570864C0 (en) | 2026-02-18 |
| EP3570864A4 (en) | 2020-12-30 |
| JP7819087B2 (ja) | 2026-02-24 |
| AU2018210174B2 (en) | 2022-04-07 |
| EP3570864A1 (en) | 2019-11-27 |
| JP2020505352A (ja) | 2020-02-20 |
| AU2018210174A1 (en) | 2019-07-25 |
| US20200207822A1 (en) | 2020-07-02 |
| EP3570864B1 (en) | 2026-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018210174B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US11845808B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US12552836B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US12018057B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US10941183B2 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| US11041000B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| WO2021007433A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| WO2021146458A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| CA2991984A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US20260116921A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230106 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240802 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240825 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241127 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241230 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250219 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251022 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20260223 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260318 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260318 |